

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19 (Cancelled).

20. (Previously presented) An isolated polypeptide comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.

21. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that added.

22. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are deleted.

23. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are conservatively substituted.

24. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6).

25. (Presently amended) An isolated polypeptide comprising an extracellular ~~region~~segment of the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6).

26. (Previously presented) The polypeptide of Claim 25, wherein the extracellular region comprises at least 10 contiguous residues.

27. (Presently amended) The polypeptide of Claim 25, wherein the extracellular ~~region~~ segment comprises the N-terminal fragment.

28. (Previously presented) The polypeptide of Claim 27, wherein the N-terminal extracellular region comprises at least 10 contiguous residues.

29. (Previously presented) A composition comprising the polypeptide of Claim 20 and a pharmaceutically acceptable carrier.

30. (Previously presented) A composition comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

31. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 20.

32. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 21.

33. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 22.

34. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 23.

35. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 24.
36. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 25.
37. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 26.
38. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 27.
39. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 28.
40. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.
41. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 40 operably linked to a promoter.
42. (Withdrawn-Previously presented) An expression vector comprising the nucleic acid molecule of Claim 41 operably linked to control sequences recognized by a host cell transformed with the vector.
43. (Withdrawn-Previously presented) A host cell transformed with the vector of Claim 42.

44. (Withdrawn-Previously presented) A method of using the nucleic acid of Claim 40, comprising culturing a host cell that has been transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.

45. (Withdrawn-Previously presented) The method of Claim 44 further comprising recovering the polypeptide from the host cell.

46. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding at least 10 contiguous amino acid residues from an extracellular domain of the PF4AR polypeptide of Figure 5 (SEQ ID NO:6).

47. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 46, wherein the encoded polypeptide is an N-terminal extracellular domain.

48. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 46 operably linked to a promoter.

49. (Withdrawn-Previously presented) An expression vector comprising the nucleic acid molecule of Claim 48 operably linked to control sequences recognized by a host cell transformed with the vector.

50. (Withdrawn-Previously presented) A host cell transformed with the vector of Claim 49.

51. (Withdrawn-Previously presented) A method of using the nucleic acid of Claim 46, comprising culturing a host cell that has been transformed with a vector comprising the nucleic

acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.

52. (Withdrawn-Previously presented) The method of Claim 51 further comprising recovering the polypeptide from the host cell.

53. (Withdrawn-Previously presented) A method for determining the presence or absence of a PF4AR nucleic acid in a sample, comprising the steps of:

- (a) selecting a probe comprising at least 20 contiguous nucleotides from the nucleic acid sequence of Figure 5 (SEQ ID NO:5);
- (b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex;
- (c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and
- (d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c).

54. (Withdrawn-Previously presented) A method of amplifying a PF4AR nucleic acid in sample, comprising the steps of:

- (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Figure 5 (SEQ ID NO:5) or at least 20 contiguous nucleotides complementary to said primer;
- (b) hybridizing the oligonucleotide primer to a single strand of the PF4AR nucleic acid in the sample, and
- (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded nucleic acid to form an amplified nucleic acid.

55. (Withdrawn-Previously presented) An antibody capable of binding to the PF4AR polypeptide of Figure 5 (SEQ ID NO:6) and that does not cross-react with other PF4AR polypeptides.

56. (Withdrawn-Previously presented) The antibody of Claim 55, which is a polyclonal antibody.

57. (Withdrawn-Previously presented) The antibody of Claim 55, which is a monoclonal antibody.

58. (Withdrawn-Previously presented) The antibody of Claim 55, which is an IgG1 isotype antibody.

59. (Withdrawn-Previously presented) An antibody capable of binding an extracellular region of the PF4AR polypeptide of Figure 5 (SEQ ID NO:6).

60. (Withdrawn-Previously presented) The antibody of Claim 59, wherein the extracellular region is an N-terminal extracellular region.

61. (Withdrawn-Previously presented) The antibody of Claim 59, wherein the extracellular region comprises at least 10 contiguous amino acid residues of Figure 5 (SEQ ID NO:6).

62. (Withdrawn-Previously presented) The antibody of Claim 59, which is a polyclonal antibody.

63. (Withdrawn-Previously presented) The antibody of Claim 59, which is a monoclonal antibody.

64. (Withdrawn-Previously presented) The antibody of Claim 59, which is an IgG1 isotype antibody.

65. (Withdrawn-Previously presented) The antibody of Claim 60, which is a monoclonal antibody.

66. (Withdrawn-Previously presented) The antibody of Claim 60, which is an IgG1 isotype antibody.

67. (Withdrawn-Previously presented) The antibody of Claim 61, which is a monoclonal antibody.

68. (Withdrawn-Previously presented) The antibody of Claim 61, which is an IgG1 isotype antibody.

69. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 55 and a pharmaceutically acceptable carrier.

70. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 59 and a pharmaceutically acceptable carrier.

71. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 63 and a pharmaceutically acceptable carrier.

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket **P0706P2C2D2C1**
Express Mail No. EV384508739 US

72. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 65 and a pharmaceutically acceptable carrier.

73. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 67 and a pharmaceutically acceptable carrier.